SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-260795
Filing Date
2023-10-23
Accepted
2023-10-23 16:07:29
Documents
13
Period of Report
2023-10-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d561418d8k.htm   iXBRL 8-K 24423
2 EX-99.1 d561418dex991.htm EX-99.1 28177
  Complete submission text file 0001193125-23-260795.txt   186089

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oric-20231021.xsd EX-101.SCH 2861
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20231021_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20231021_pre.xml EX-101.PRE 11715
7 EXTRACTED XBRL INSTANCE DOCUMENT d561418d8k_htm.xml XML 3480
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

IRS No.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 231340078
SIC: 2834 Pharmaceutical Preparations